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Metachronous Eyelid Basal Cell Carcinoma on Opposite Eye and Lid: A Case
Report
Abstract
Background: Basal cell carcinoma (BCC) is the most common eyelid malignancy, accounting for
approximately 90% of malignant eyelid lesions.1 Despite its high occurrence rates, it is frequently
misdiagnosed as one of the benign “lumps and bumps” that can be present on the eyelid. In the present
case, a patient with a past BCC on the right upper eyelid presented with a left lower eyelid lesion which
persisted for months before the patient sought evaluation by an eyecare provider. This benign-looking
lash-line lesion was the only external sign of the malignancy found on the deep surface of the eyelid and
later diagnosed as BCC.
Case Report: A 74-year-old patient presented with a persistent eyelid lesion that was resistant to
treatment for greater than 6 months. The small lesion was slightly suspicious in appearance. Further
evaluation revealed a larger, more irregular lesion on the conjunctival surface of the eyelid. The patient
was referred to an oculoplastic specialist for biopsy. Pathology confirmed the diagnosis of basal cell
carcinoma.
Conclusion: Once the lesion was properly diagnosed, the patient underwent Mohs micrographic surgery
and eyelid reconstruction. This case will highlight the importance of prompt and thorough evaluation of
suspicious eyelid lesions which are persistent and resistant to treatment in patients with a history of
eyelid malignancy.
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INTRODUCTION
Basal cell carcinoma (BCC) is the most common eyelid malignancy, accounting
for approximately 90% of malignant eyelid lesions.1 Despite its high occurrence
rates, it is frequently misdiagnosed as one of the benign “lumps and bumps” that
can be present on the eyelid. In the present case, a patient with a past BCC on the
right upper eyelid presented with a left lower eyelid lesion which persisted for
months before the patient sought evaluation by an eyecare provider. This benignlooking lash-line lesion was the only external sign of the malignancy found on the
deep surface of the eyelid and later diagnosed as BCC.
CASE REPORT
A 74-year-old male presented for his annual diabetic eye exam. His medical
history included insulin-dependent diabetes for five years without evidence of
diabetic retinopathy; physiologic optic nerve cupping; and a right upper eyelid BCC
treated successfully with Mohs micrographic surgery (MMS) approximately five
years prior. He had not followed up with the oculoplastic surgeon after the
procedure.
During his examination, the patient complained of a bump on his left lower eyelid
for approximately 6-8 months. His primary care physician had originally prescribed
antibiotic eye ointment, but the antibiotic ointment “did nothing” for the “bump.”
During the same period, the patient also had been applying warm compresses to the
lesion, but he stopped after a few weeks due to lack of improvement. At the time
of his appointment, his only symptom related to the lesion was a foreign body
sensation on blink.
On physical examination, best corrected acuity was 20/25 for the right eye and left
eyes. All external testing including pupils, motilities, and confrontation visual
fields were normal. Intraocular pressure was normal and symmetric. Scarring of the
central right upper eyelid margin was consistent with the patient’s history of MMS
and reconstruction was present. The left lower eyelid demonstrated a raised, firm,
pearly lesion without telangiectasia and with mild interruption of the lash-line
integrity. The patient did not report any tenderness when the lesion was palpated.
At first glance, the lesion appeared to be a chalazion remnant. (See Figure 1).
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Figure 1 Left lower eyelid lesion

Upon pulling down the lid and viewing the tarsal conjunctiva, a multilobulated
cystic lesion was identified. (See Figure 2).

Figure 2. Left lower eyelid tarsal conjunctiva, a multilobulated cystic lesion
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There were no notable cornea findings. The patient’s dilated retinal exam was
within normal limits; the previously noted optic nerve cupping was stable. No
diabetic retinopathy was present in either eye.
This patient was referred to an oculoplastic specialist for biopsy of the left lower
eyelid lesion. Biopsy confirmed the diagnosis of BCC and the patient was
scheduled for Mohs micrographic surgery and eyelid reconstruction.
DISCUSSION
Approximately 20% of periorbital skin lesions are malignant. Clinical
differentiation between malignant and benign eyelid lesions may be challenging
even for experienced providers. The most common benign lid lesions are chalazia,
seborrheic keratoses and inclusion cysts. The most common malignancies are BCC,
squamous cell carcinoma, and sebaceous cell carcinoma.2,3 Five main factors that
should be evaluated for which increase malignancy risk are asymmetry, irregular
borders, colors that are not uniform, diameter (greater than 6 mm), and enlargement
or elevation (represented by a mnemonic ABCDE). Leung et al. proposed an
additional three factors: lash-loss, ulceration, and infiltration (or mnemonic LUI)
for identification of malignant lesions. In a study of 199 eyelid lesions these factors
were the three most predictive of malignancy.3
Clinical differentiation among malignant lesions can be difficult as well.
Sebaceous cell carcinoma is differentiated by its association with the glands of Zeis;
it also has a characteristic yellow coloration due to lipoid deposition and can present
with chronic localized blepharoconjunctivitis and chalazia. Squamous cell
carcinoma may arise from pre-malignant lesions such as actinic keratosis, Bowen’s
disease, or keratoacanthoma. It can present with varying features from
erythematous scaly patches to ulcerated or nodular lesions.4 BCC is not easily
differentiated from squamous cell carcinoma and diagnosis is often not determined
until a biopsy is performed.2
Basal cell carcinoma of the eyelid most commonly presents as a pink or fleshy
pearlescent nodule—occasionally with ulceration or telangiectasia.5 This nodular
presentation accounts for up to 80% of cases on the head and face.6 A less common
variant, morpheaform BCC, involves fibroblastic proliferation in addition to the
classic tumor cell production. This type is more aggressive, has a higher recurrence
rate, and requires greater caution when clearing excisional margins. The distinction
is made histochemically by the presence of alpha-actin in the tumor stroma.
Clinically, these lesions appear as white-yellow shiny plaques.7,6 Infiltrative BCC
lesions are a variant in which the tumor cells extend deeper into the dermis than
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typical nodular presentation; the extent of this type is often underestimated before
a Mohs excision is performed. Superficial BCC is another rare variant which mostly
occurs on body skin. It appears as an erythematous plaque like that associated with
psoriasis or eczema.6
Eyelid BCC accounts for approximately 10% of all BCC lesions and primarily
results from UV exposure. Additional risk factors include advanced age,
immunosuppression, and exogenous carcinogens.6,8 The incidence of BCC on
eyelids is similar in females and males and higher in Caucasian populations.6,9
According to Hamada et al., 76% of lesions are located on the lower eyelid,
15% on the upper eyelid, and the remainder on the medial canthus and lateral
canthus.10
The gold standard for diagnosis of BCC is biopsy and histopathology. Though
rapid metastasis is not typical of BCC, location on the eyelid or adnexa still requires
prompt and careful management by an oculoplastic specialist to avoid localized
spread and to achieve an aesthetically pleasing and anatomically successful
outcome.9 Treatment options include surgical intervention, radiation therapy, and
drug therapies including Vismodegib or Imiquimod. Surgical resection is the most
effective treatment option followed closely by wide local excision (with
intraoperative frozen sections).1,11 The indication for radiation therapy or drug
therapy is the inability to tolerate surgical resection, such as in a very sick patient
or a patient with many serious comorbidities.11 Surgical resection is the most
effective treatment option, with a cure rate greater than 95% (up to 99%) depending
on size, variety and location. Other treatment options (e.g., radiation therapy) are
generally less effective but still have a cure rate of over 90%.1
The recurrence rate of BCC after MMS is minimal at approximately 3%. 25% of
recurrences occur within the first year and 75% within three years; the median time
to recurrence being 19 months.12 Having a history of BCC or squamous cell
carcinoma does increase the risk of developing additional lesions and a history of
the latter increases the risk greater than the former. Patients who have a history of
both BCC and squamous cell have a greater risk of subsequent BCC lesions than
those with a history of BCC alone. Older age increases risk of future lesions; the
average age of those with additional lesions being 69 years-old versus an average
age of 63 years-old without.13
When Smedinga et al. investigated the risk of metachronous BCC lesions (isolated
additional lesions identified later), they found that the greatest prognostic indicator
was the number of previous BCC lesions. Other risk factors were skin sensitivity
to sunburn (i.e., Fitzpatrick classification), pigmentation of previous lesions, and
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lesion location. Utilizing the relative risks of these factors, a prognostic model was
developed. A score was assigned for each risk factor and the sum used to determine
a patient’s relative risk of developing metachronous lesions at 1 year, 3 years and
5 years in hopes of individualizing appropriate surveillance.14
CONCLUSION
The present case should remind eye care practitioners of ABCDE and LUI factors
for the evaluation of suspicious periorbital skin lesions. Also, that biopsy should be
considered for any eyelid lesion that does not respond to treatment, particularly in
patients with a history of eyelid malignancy.2 It is imperative to educate at-risk
patients that regular monitoring and prompt evaluation are necessary for any new
lesions or growths.
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